La desacetilación de SRF catalizada por SIRT7 protege contra la formación de aneurisma de aorta abdominal

ubiquitin-mediated degradation and preserving the VSMC contractile phenotype. Consequently, SIRT7 deficiency enhances SRF acetylation, accelerates its degradation, and promotes VSMC phenotypic switching, ultimately facilitating AAA progression. Pharmacological activation of SIRT7 with the NAD⁺ precursor nicotinamide mononucleotide attenuated aortic dilation. Collectively, our findings reveal a crucial role for SIRT7-mediated SRF-K154 deacetylation in limiting AAA progression and suggest that nicotinamide mononucleotide supplementation may represent a promising therapeutic strategy for AAA.